Drug
Enfuvirtide clinical trials
Also written Fuzeon and T-20.
- studies test it
- 30
- open now
- 0
- in phase 3
- 5
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2005 (6)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 1 |
| 2008 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 8
- Phase 3
- 5
- Phase 4
- 10
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 14
Hoffmann-La Roche (14) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · French National Agency for Research on AIDS and Viral Hepatitis (3) · Trimeris (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Maryland, Baltimore (1) · Canadian Immunodeficiency Research Collaborative (1) · Hospital Clinic of Barcelona (1)
Often tested with
Tested in the same studies.
Etravirine (2) · Raltegravir (1) · Darunavir (1) · Tipranavir (1) · Maraviroc (1) · Amdoxovir (1) · Darunavir/Ritonavir (1) · Valproic Acid (1)
Studies
Open first, then newest update. How each study uses Enfuvirtide is read from its arms, and is right about nine times in ten.
Testing it · 30
- Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00302822Written as enfuvirtide
- Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)CompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00120367Written as Enfuvirtide
- Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 IndividualsCompletedEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01836068Written as Enfuvirtide
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00537394Written as Enfuvirtide
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00051831Written as Enfuvirtide
- Adding New Drugs for HIV Infected Patients Failing Current TherapyCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00031044Written as Enfuvirtide
- Study of a New Anti-HIV Drug, T-20, in HIV-Infected ChildrenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001118Written as Enfuvirtide
- A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of TherapyCompletedPhase 4University of Maryland, BaltimoreNCT00344760Written as Enfuvirtide
- A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1TerminatedPhase 4Hoffmann-La RocheNCT00100984Written as FUZEON [enfuvirtide]
- A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected PatientsCompletedPhase 2Hoffmann-La RocheNCT00089492Written as enfuvirtide [Fuzeon]
- QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) InfectionCompletedPhase 4Hoffmann-La RocheNCT00232908Written as enfuvirtide [Fuzeon]
- A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) InfectionCompletedPhase 4Hoffmann-La RocheNCT02569502Written as enfuvirtide
- BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.CompletedPhase 4Hoffmann-La RocheNCT00326963Written as enfuvirtide [Fuzeon]
- A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) InfectionCompletedPhase 4Hoffmann-La RocheNCT02582983Written as Enfuvirtide
- Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) InfectionCompletedPhase 3Hoffmann-La RocheNCT02733419Written as Enfuvirtide
- T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and AdolescentsCompletedPhase 2Hoffmann-La RocheNCT00022763Written as Enfuvirtide
- BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 InfectionCompletedPhase 4Hoffmann-La RocheNCT00337701Written as enfuvirtide [Fuzeon]
- WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.CompletedPhase 4Hoffmann-La RocheNCT00233883Written as enfuvirtide [Fuzeon]
- A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment ExperienceCompletedPhase 4Hoffmann-La RocheNCT00487188Written as Enfuvirtide
- INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.CompletedPhase 2Hoffmann-La RocheNCT00615134Written as enfuvirtide [Fuzeon]
See all 30 studies that test Enfuvirtide →
Given in every arm · 3 — Enfuvirtide is usual care beside what is tested
- ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.WithdrawnPhase 4Hoffmann-La RocheNCT00461266Written as enfuvirtide [Fuzeon]
- A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyCompletedPhase 2Tibotec Pharmaceuticals, IrelandNCT00128830Written as Enfuvirtide (ENF)
- A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected PatientsTerminatedPhase 4Hoffmann-La RocheNCT00488059Written as enfuvirtide [Fuzeon]
Codes
What other systems call Enfuvirtide · ClinicalTrials.gg INT006755
- MeSH (NLM) D000077560EnfuvirtideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 19OWO1T3ZEENFUVIRTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 139896Confirmed FDA, Wikidata
- Wikidata Q423327enfuvirtideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2105EnfuvirtideOne source FDA
- DrugBank DB00109One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077560 | Enfuvirtide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 19OWO1T3ZE | ENFUVIRTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 139896 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423327 | enfuvirtide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2105 | Enfuvirtide | One source FDA |
| DrugBank | DB00109 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.